With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1067915-34-7,Ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate,as a common compound, the synthetic route is as follows.
To a suspension of NaH (about 60% in oil, 0.27 g, about 6.8 mmol) in THF (20 mL) was added compound T” (1.01 g, 3.4 mmol) in THF (15 mL), at 0C. After 30 min the ice bath was removed and Tf2NPh (1.82 g, 5.1 mmol) was added. The mixture was heated at 45 C for 72 h. The mixture was allowed to cool to rt, ice was added, and the THF was evaporated under reduced pressure. EtOAc was added, the phases were separated and the organic phase was washed with aq. 10% Na2C03 (lx). The org. extracts were dried over MgS04, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 5: 95 o 1: 9) yielded the title compound (1.46 g, quantitative yield). LC-MS: Rt = 1. 13 min, ES+: 430.13.
1067915-34-7, The synthetic route of 1067915-34-7 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; ACTELION PHARMACEUTICALS LTD; WO2005/40120; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem